



ASX RELEASE

6 November 2017

Paradigm Completes Significantly Oversubscribed Placement to Raise A\$5.75 million

Key Highlights:

- Paradigm raises A\$5.75 million via a significantly oversubscribed Placement.
- Raising was expanded to meet very strong demand from existing and new institutional, sophisticated and professional investors.
- Raising means Paradigm is well funded into CY2019 and importantly, post the completion of the Phase 2 Ross River virus and one-hundred participant Phase 2b Osteoarthritis trials due to be completed at the end of CY2018.
- Paradigm CEO and MD Paul Rennie participated in the Placement (subject to shareholder approval) and increased his holding by \$100,000 as did other members of Paradigm's management team.

Paradigm Biopharmaceuticals Ltd (ASX: PAR) is pleased to announce it has completed a Placement to raise A\$5.75 million ("Placement").

The Placement was expanded due to very strong demand from existing and new institutional, sophisticated and professional investors. Paradigm is pleased to welcome these new institutions to its register.

The capital raising means that Paradigm is well funded into CY2019 and importantly, post the completion of the Phase 2 Ross River virus and one-hundred participant Phase 2b Osteoarthritis trials due to be completed at the end of CY2018.

The Placement was conducted at an issue price of A\$0.30 a share. This represents a 16.7% discount to Paradigm's last closing price of A\$0.36 (as at Wednesday, November 1, 2017).

The proceeds from the Placement will primarily be used to fund:

- The completion of the randomised, double-blind, placebo-controlled Phase 2b clinical trial in one-hundred subjects with Osteoarthritis (OA) and concurrent Bone Marrow Edema Lesions (BMELs);
- The ongoing generation of Real-World-Evidence data in subjects with OA and concurrent BMEL's;
- The expansion of the BMEL market into other joint and pain indications;
- The initiation of a pilot Phase 2 clinical trial in Chikungunya;
- Generation of Intellectual Property; and
- Working capital requirements.

The Placement Shares will be issued in accordance with ASX Listing Rule 7.1 and 7.1A under the Company's existing 15% and 10% placement capacity. After these shares are issued, the placement would comprise 15.8% of the total issued share capital and will rank equally with existing ordinary shares.

Mr Paul Rennie, Paradigm's Chief Executive Officer said: "The strong support of institutional and sophisticated investors in this capital raising is a solid endorsement of our Company and places Paradigm in a very strong position to accelerate our two Phase 2 clinical trials."

"Importantly, it means our Company is well funded post the completion of our key Phase 2 Ross River virus and Osteoarthritis trials due to be completed by the end of CY2018."

Baker Young Stockbrokers Limited and Morgans Corporate Limited acted as Joint Lead Managers to the Placement.

Placement Timetable

The dates provided in the timetable below are indicative only and are subject to change at the Company's complete discretion.

Placement announced and Company's shares re-commence trading on the ASX	Monday, 6 November 2017
Settlement and issue of Placement Shares	Monday, 13 November 2017
Allotment of Placement Shares	Tuesday, 14 November 2017
Expected date of quotation of Placement Shares on the ASX	Tuesday, 14 November 2017

FOR FURTHER INFORMATION PLEASE CONTACT:

Paul Rennie

Director & CEO

Paradigm Biopharmaceuticals Ltd

Level 2, 517 Flinders Lane, Melb, VIC, 3000, AUSTRALIA

ABN: 94 169 346 963

Web: <http://paradigmbiopharma.com/>

Email: prennie@paradigmbiopharma.com

Mobile International: +61 437 778 300

Mobile (Australia): 0437 778 300